Medistem Inc. Annual Letter to Shareholders

SAN DIEGO, CA–(Marketwire – Jan 4, 2013) – Medistem Inc. ( PINKSHEETS : MEDS ) today issues the following letter to shareholders. Dear Fellow Shareholders, 2012 was marked by significant progress in the development of the Endometrial Regenerative Cell (ERC), our new universal donor “stem cell drug.” Most significantly, we initiated a double blind, placebo…

Arteriocyte gets FDA approval to begin critical limb ischemia clinical trial

Medcity News Critical limb ischemia is an advanced form of peripheral artery disease that causes hundreds of thousands of amputations per year. This condition is attractive to stem cell intervention because even a marginal improvement in circulation may be enough to prevent amputation. Previous work from Japan and Mike Murphy’s group at Indiana has demonstrated…